Behçet disease: Difference between revisions
From IDWiki
(Created page with "== Diagnostic Criteria == * Recurrent oral ulcerations (aphthous or herpetiform) at least three times in one year * Any two of the following: ** Recurrent...") |
No edit summary |
||
Line 1: | Line 1: | ||
== Clinical Manifestations == |
|||
* Skin and mucosal |
|||
** '''Oral ulcers''' (98%), which are usually painful, recurrent, and can involve the soft and hard palate, buccal mucosa, tongue, gingiva, lips, and tonsils, and usually heal without scarring |
|||
** '''Genital ulcers''' (65%): recurrent, mostly heal ''with'' scarring, most commonly on scrotum in men and vulva or vagina in women |
|||
** Orchiepididymitis (6%) |
|||
** '''Skin lesion''' (75%), including [[pseudofolliculitis]], acne-like papulopustular lesions, [[erythema nodosum]], positive [[pathergy test]] |
|||
* '''Joints''' (50%) |
|||
** [[Oligoarticular arthritis]]: primarily involving knees, ankles, wrists, and elbows; non-erosive and non-deforming, and more common in patients with acneiform skin lesions |
|||
** Can be a [[polyarticular arthritis]] as well |
|||
** Usually excludes [[sacroiliitis]] |
|||
** [[Enthesopathy]] |
|||
* '''Ocular''' (50%): [[hypopyon]], non-granulomatous [[panuveitis]], [[retinal vasculitis]] |
|||
* CNS involvement (10-30%): mesodiencephalic and brain-stem inflammation, encephalitis, meningitis, myelitis, neurocognitive dysfunction, cerebral-vein thrombosis |
|||
* Cardiovascular |
|||
** Arterial (2-18%): arterial aneurysms, arterial stenosis, arterial thrombosis |
|||
** Cardiac (6%): valvulitis, myopericarditis, coronary arteritis |
|||
** Venous (15-40%): [[DVT]], [[superficial thrombophlebitis]] |
|||
* Gastrointestinal (0-20%): mucosal ulcers, abdominal pain, hemorrhage, perforation |
|||
== Diagnostic Criteria == |
== Diagnostic Criteria == |
||
=== ICBD 2014 === |
|||
⚫ | |||
* Criteria: |
|||
** Recurrent oral ulcers (2 points) |
|||
** Genital ulcers (2 points) |
|||
** Ocular lesions (2 points) |
|||
** Skin lesions (1 point) |
|||
** Vascular manifestations (1 point) |
|||
** Neurologic manifestations (1 point) |
|||
** Positive pathergy test (optional) (1 point) |
|||
* Interpretation: diagnosis based on ≥4 points |
|||
** Sensitivity 95%, specificity 92% |
|||
=== ISG 1990 === |
|||
⚫ | |||
* Any two of the following: |
* Any two of the following: |
||
** Recurrent genital ulcerations |
** Recurrent genital ulcerations |
||
Line 7: | Line 41: | ||
** Skin lesions ([[erythema nodosum]], [[pseudofolliculitis]], [[Papulopustular lesion|papulopustular lesions]], [[Aceiform nodule|aceiform nodules]]) in adult patients not treated with corticosteroids |
** Skin lesions ([[erythema nodosum]], [[pseudofolliculitis]], [[Papulopustular lesion|papulopustular lesions]], [[Aceiform nodule|aceiform nodules]]) in adult patients not treated with corticosteroids |
||
** Positive [[pathergy test]] read by a physician at 24 to 48 hours |
** Positive [[pathergy test]] read by a physician at 24 to 48 hours |
||
* Sensitivity 95%, specificity 96% |
|||
== Management == |
|||
* Isolated skin and mucosal ulcers: tropical treatments for active ulcers, with [[colchicine]] as preventative treatment |
|||
* Refractory or widespread lesions or ulcers: prednisone 15 mg daily for 1 week, followed by a taper over several weeks |
|||
* Other options for more advanced presentations include systemic glucocorticoids, [[azathioprine]], [[TNF-α inhibitors]], |
|||
== Further Reading == |
|||
* Behçet Syndrome. ''NEJM'' 2024;390(7):640-651. doi: [https://doi.org/10.1056/NEJMra2305712 10.1056/NEJMra2305712] |
|||
[[Category:Dermatology]] |
[[Category:Dermatology]] |
Latest revision as of 16:28, 13 March 2024
Clinical Manifestations
- Skin and mucosal
- Oral ulcers (98%), which are usually painful, recurrent, and can involve the soft and hard palate, buccal mucosa, tongue, gingiva, lips, and tonsils, and usually heal without scarring
- Genital ulcers (65%): recurrent, mostly heal with scarring, most commonly on scrotum in men and vulva or vagina in women
- Orchiepididymitis (6%)
- Skin lesion (75%), including pseudofolliculitis, acne-like papulopustular lesions, erythema nodosum, positive pathergy test
- Joints (50%)
- Oligoarticular arthritis: primarily involving knees, ankles, wrists, and elbows; non-erosive and non-deforming, and more common in patients with acneiform skin lesions
- Can be a polyarticular arthritis as well
- Usually excludes sacroiliitis
- Enthesopathy
- Ocular (50%): hypopyon, non-granulomatous panuveitis, retinal vasculitis
- CNS involvement (10-30%): mesodiencephalic and brain-stem inflammation, encephalitis, meningitis, myelitis, neurocognitive dysfunction, cerebral-vein thrombosis
- Cardiovascular
- Arterial (2-18%): arterial aneurysms, arterial stenosis, arterial thrombosis
- Cardiac (6%): valvulitis, myopericarditis, coronary arteritis
- Venous (15-40%): DVT, superficial thrombophlebitis
- Gastrointestinal (0-20%): mucosal ulcers, abdominal pain, hemorrhage, perforation
Diagnostic Criteria
ICBD 2014
- Criteria:
- Recurrent oral ulcers (2 points)
- Genital ulcers (2 points)
- Ocular lesions (2 points)
- Skin lesions (1 point)
- Vascular manifestations (1 point)
- Neurologic manifestations (1 point)
- Positive pathergy test (optional) (1 point)
- Interpretation: diagnosis based on ≥4 points
- Sensitivity 95%, specificity 92%
ISG 1990
- Recurrent oral ulcerations (aphthous or herpetiform) at least three times in one year, plus
- Any two of the following:
- Recurrent genital ulcerations
- Eye lesions 9uveitis or retinal vasculitis) observed by an ophthalmologist
- Skin lesions (erythema nodosum, pseudofolliculitis, papulopustular lesions, aceiform nodules) in adult patients not treated with corticosteroids
- Positive pathergy test read by a physician at 24 to 48 hours
- Sensitivity 95%, specificity 96%
Management
- Isolated skin and mucosal ulcers: tropical treatments for active ulcers, with colchicine as preventative treatment
- Refractory or widespread lesions or ulcers: prednisone 15 mg daily for 1 week, followed by a taper over several weeks
- Other options for more advanced presentations include systemic glucocorticoids, azathioprine, TNF-α inhibitors,
Further Reading
- Behçet Syndrome. NEJM 2024;390(7):640-651. doi: 10.1056/NEJMra2305712